BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 16, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tivozanib: Completed Phase III enrollment

Aveo completed enrollment of 500 patients in an open-label, international Phase III trial comparing 1.5 mg oral tivozanib vs. 400 mg oral Nexavar sorafenib for 24 months. The company has...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >